Novel Immunotherapies for T Cell Lymphoma and Leukemia. Review uri icon

Overview

abstract

  • PURPOSE OF REVIEW: Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia. RECENT FINDINGS: For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists. In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.

publication date

  • December 1, 2018

Research

keywords

  • Immunotherapy
  • Leukemia
  • Lymphoma, T-Cell

Identity

PubMed Central ID

  • PMC6295363

Scopus Document Identifier

  • 85055266370

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.ccr-08-1254

PubMed ID

  • 30317410

Additional Document Info

volume

  • 13

issue

  • 6